JP2018524349A5 - - Google Patents

Download PDF

Info

Publication number
JP2018524349A5
JP2018524349A5 JP2017568261A JP2017568261A JP2018524349A5 JP 2018524349 A5 JP2018524349 A5 JP 2018524349A5 JP 2017568261 A JP2017568261 A JP 2017568261A JP 2017568261 A JP2017568261 A JP 2017568261A JP 2018524349 A5 JP2018524349 A5 JP 2018524349A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017568261A
Other languages
English (en)
Japanese (ja)
Other versions
JP7203497B2 (ja
JP2018524349A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/039797 external-priority patent/WO2017004026A1/en
Publication of JP2018524349A publication Critical patent/JP2018524349A/ja
Publication of JP2018524349A5 publication Critical patent/JP2018524349A5/ja
Priority to JP2022209445A priority Critical patent/JP7611218B2/ja
Application granted granted Critical
Publication of JP7203497B2 publication Critical patent/JP7203497B2/ja
Priority to JP2024226350A priority patent/JP2025041791A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017568261A 2015-06-29 2016-06-28 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体 Active JP7203497B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022209445A JP7611218B2 (ja) 2015-06-29 2022-12-27 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体
JP2024226350A JP2025041791A (ja) 2015-06-29 2024-12-23 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562186161P 2015-06-29 2015-06-29
US62/186,161 2015-06-29
US201662338203P 2016-05-18 2016-05-18
US62/338,203 2016-05-18
US201662346730P 2016-06-07 2016-06-07
US62/346,730 2016-06-07
PCT/US2016/039797 WO2017004026A1 (en) 2015-06-29 2016-06-28 Anti-cd 123 antibodies and conjugates and derivatives thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022209445A Division JP7611218B2 (ja) 2015-06-29 2022-12-27 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体

Publications (3)

Publication Number Publication Date
JP2018524349A JP2018524349A (ja) 2018-08-30
JP2018524349A5 true JP2018524349A5 (https=) 2019-08-08
JP7203497B2 JP7203497B2 (ja) 2023-01-13

Family

ID=56373176

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017568261A Active JP7203497B2 (ja) 2015-06-29 2016-06-28 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体
JP2022209445A Active JP7611218B2 (ja) 2015-06-29 2022-12-27 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体
JP2024226350A Pending JP2025041791A (ja) 2015-06-29 2024-12-23 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022209445A Active JP7611218B2 (ja) 2015-06-29 2022-12-27 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体
JP2024226350A Pending JP2025041791A (ja) 2015-06-29 2024-12-23 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体

Country Status (27)

Country Link
US (6) US10077313B2 (https=)
EP (2) EP3313884B9 (https=)
JP (3) JP7203497B2 (https=)
KR (3) KR102663480B1 (https=)
CN (4) CN120248124A (https=)
AR (1) AR105194A1 (https=)
AU (2) AU2016285552B2 (https=)
BR (1) BR112017027254A2 (https=)
CA (1) CA2989321A1 (https=)
CY (1) CY1123884T1 (https=)
DK (1) DK3313884T3 (https=)
ES (1) ES2887273T3 (https=)
HR (1) HRP20210263T1 (https=)
HU (1) HUE053619T2 (https=)
IL (2) IL256271B (https=)
LT (1) LT3313884T (https=)
MD (1) MD3313884T2 (https=)
PL (1) PL3313884T3 (https=)
PT (1) PT3313884T (https=)
RS (1) RS61452B9 (https=)
RU (1) RU2739612C2 (https=)
SG (1) SG10202005144TA (https=)
SI (1) SI3313884T1 (https=)
SM (1) SMT202100092T1 (https=)
TW (3) TW202423981A (https=)
WO (1) WO2017004026A1 (https=)
ZA (1) ZA202007918B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164916A1 (en) 2015-04-10 2016-10-13 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes
EP3769787A1 (en) 2015-06-29 2021-01-27 ImmunoGen, Inc. Conjugates of cysteine engineered antibodies
ES2887273T3 (es) * 2015-06-29 2021-12-22 Immunogen Inc Anticuerpos anti-CD123 y conjugados y derivados de los mismos
PT3380525T (pt) 2015-11-25 2024-02-05 Immunogen Inc Formulações farmacêuticas e métodos que as utilizam
TWI845890B (zh) 2016-11-23 2024-06-21 美商伊繆諾金公司 苯二氮平衍生物之選擇性磺化
WO2018129029A1 (en) * 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
EP4148044A1 (en) 2017-01-25 2023-03-15 ImmunoGen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
KR20250171447A (ko) 2017-02-28 2025-12-08 이뮤노젠 아이엔씨 자기희생적 펩티드 링커 및 이들의 접합체를 갖는 메이탄시노이드 유도체
CN111372610B (zh) * 2017-09-22 2023-05-30 伊缪诺金公司 防止免疫结合物中的甲硫氨酸氧化的方法
JP2020534332A (ja) * 2017-09-22 2020-11-26 イミュノジェン， インコーポレイテッド カチオン交換クロマトグラフィーを使用した三重軽鎖抗体の分離
IL301637B2 (en) 2017-09-29 2024-10-01 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
JP7324749B2 (ja) * 2017-10-27 2023-08-10 ファイザー・インク Ｃｄ１２３に特異的な抗体および抗体－薬物コンジュゲートならびにその使用
WO2019108863A1 (en) 2017-11-29 2019-06-06 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd5+ cells
US12201154B2 (en) 2018-01-03 2025-01-21 Cqens Technologies Inc. Heat-not-burn device and method
MA51629A (fr) 2018-01-12 2020-11-18 Immunogen Inc Procédés de production, purification et formulation de conjugués anticorps-médicaments
CN116425874A (zh) * 2018-06-15 2023-07-14 康源博创生物科技(北京)有限公司 抗cd123抗体及其制备方法和应用
US20200157228A1 (en) * 2018-10-30 2020-05-21 Immunogen, Inc. Methods of treatment using anti-cd123 immunoconjugates
WO2020092344A1 (en) * 2018-10-31 2020-05-07 Health Research, Inc. Combination treatment with anti-cd123 antibody drug conjugate and parp inhibitor
TWI849000B (zh) * 2018-11-12 2024-07-21 美商伊繆諾金公司 製備細胞毒性苯二氮呯衍生物之方法
KR20210098470A (ko) * 2018-11-12 2021-08-10 이뮤노젠 아이엔씨 세포독성 벤조디아제핀 유도체의 제조 방법
CA3125751A1 (en) * 2019-01-07 2020-07-16 Magenta Therapeutics, Inc. Use of an anti-cd45 antibody drug conjugate (adc) in cell therapy
US11833214B2 (en) 2019-03-21 2023-12-05 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
EP3947395A1 (en) 2019-03-29 2022-02-09 ImmunoGen, Inc. Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases
CA3137454A1 (en) * 2019-04-29 2020-11-05 Immunogen, Inc. Therapeutic combinations comprising anti-cd123 immunoconjugates
US20220306751A1 (en) * 2019-09-13 2022-09-29 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
CN112646033B (zh) * 2020-12-16 2022-04-12 北京艺妙神州医药科技有限公司 靶向cd123的嵌合抗原受体及其用途
CA3232764A1 (en) 2021-09-30 2023-04-06 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pyrrolo benzodiazepine derivative, and conjugate, preparation method and use thereof
CN120957754A (zh) * 2023-05-12 2025-11-14 四川科伦博泰生物医药股份有限公司 稠环化合物及其制备方法和用途
WO2025027472A2 (en) 2023-07-31 2025-02-06 Astrazeneca Ab Cd123 antibody-drug conjugates and methods of using the same
US20250345449A1 (en) 2024-05-10 2025-11-13 Immunogen, Inc. Anti-cd123 immunoconjugates for the treatment of blastic plasmacytoid cell neoplasm
WO2025235924A2 (en) 2024-05-10 2025-11-13 Immunogen, Inc. Anti-cd123 immunoconjugates for the treatment of acute myeloid leukemia

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
WO1990014443A1 (en) 1989-05-16 1990-11-29 Huse William D Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
BR0316101A (pt) 2002-11-07 2005-09-27 Immunogen Inc Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
HRP20130494T1 (en) * 2005-12-20 2013-08-31 Sbi Biotech Co., Ltd. Anti-ilt7 antibody
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
WO2008127735A1 (en) * 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
EP2275431A3 (en) 2008-01-18 2011-05-25 Bio-Rad Laboratories, Inc. Enhanced fractionation of phosphorylated and nonphosphorylated biomolecules by apatite chromotography
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
US20100209341A1 (en) 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
US8492119B2 (en) * 2009-04-27 2013-07-23 Kyowa Hakko Kirin Co., Ltd Antibody to human IL-3 receptor alpha chain
CN102821815A (zh) 2010-02-18 2012-12-12 Csl有限公司 慢性炎症状态的治疗
CN103037900B (zh) 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
BR112012030311A2 (pt) 2010-06-08 2017-01-24 Genentech Inc anticorpo
NZ604510A (en) * 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
JP6049642B2 (ja) 2011-02-15 2016-12-21 イミュノジェン・インコーポレーテッド 複合体の調製方法
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
US20160031996A1 (en) 2013-03-14 2016-02-04 Csl Limited Anti il-3r alpha agents and uses thereof
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
CN105814082A (zh) * 2013-09-26 2016-07-27 埃博灵克斯股份有限公司 双特异性纳米抗体
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
CN106456762A (zh) * 2014-05-20 2017-02-22 伊缪诺金公司 用于表征和治疗急性髓样白血病的方法
TW201609152A (zh) 2014-09-03 2016-03-16 免疫原公司 包含細胞結合劑及細胞毒性劑之偶聯物
ES2815353T3 (es) * 2014-09-03 2021-03-29 Immunogen Inc Derivados de benzodiazepina citotóxicos
JO3568B1 (ar) * 2014-09-05 2020-07-05 Janssen Pharmaceutica Nv عوامل ربط cd123 واستخداماتها
ES2887273T3 (es) 2015-06-29 2021-12-22 Immunogen Inc Anticuerpos anti-CD123 y conjugados y derivados de los mismos
EP3769787A1 (en) 2015-06-29 2021-01-27 ImmunoGen, Inc. Conjugates of cysteine engineered antibodies
PT3380525T (pt) * 2015-11-25 2024-02-05 Immunogen Inc Formulações farmacêuticas e métodos que as utilizam
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor
TWI845890B (zh) * 2016-11-23 2024-06-21 美商伊繆諾金公司 苯二氮平衍生物之選擇性磺化
JP2020534332A (ja) * 2017-09-22 2020-11-26 イミュノジェン， インコーポレイテッド カチオン交換クロマトグラフィーを使用した三重軽鎖抗体の分離
CN111372610B (zh) * 2017-09-22 2023-05-30 伊缪诺金公司 防止免疫结合物中的甲硫氨酸氧化的方法
MA51629A (fr) 2018-01-12 2020-11-18 Immunogen Inc Procédés de production, purification et formulation de conjugués anticorps-médicaments

Similar Documents

Publication Publication Date Title
JP2018524349A5 (https=)
RU2017146345A (ru) Анти-cd123 антитела и их конъюгаты и производные
US11834498B2 (en) Biparatopic FR-alpha antibodies and immunoconjugates
US11584801B2 (en) Anti-5T4 antibodies and antibody-drug conjugates
US10912842B2 (en) CD123 antibodies and conjugates thereof
CN110240655B (zh) 抗her2抗体及其缀合物
ES2787180T3 (es) Lanzaderas de transporte al cerebro de anticuerpos anti-tau(pS422) humanizados y uso de las mismas
HK1221153A1 (zh) 抗体-药物缀合物
JP2012522513A5 (https=)
CN111110862A (zh) 抗cldn18．2抗体的药物偶联体及其制备方法和用途
JPWO2021213434A5 (https=)
JP7726534B2 (ja) 抗ｂ７ｈ４抗体及びその二重特異性抗体および用途
JP2014509835A5 (https=)
IL305954A (en) Nectin-4 protein antibody and extacan compounds
CN113906054A (zh) 能够结合cd19和cd3的多特异性抗原结合蛋白及其用途
KR20220140786A (ko) 클라우딘18.2 항체 및 그것의 사용
JPWO2020086665A5 (https=)
CN114829405B (zh) 抗bcma/抗4-1bb双特异性抗体及其用途
US20250066499A1 (en) Antibody binding to human cd73, preparation method therefor, and use thereof
JP7811028B2 (ja) ヒトｃｘｃｌ１６抗体およびその使用
CN120829509A (zh) 抗ror1抗体、其免疫缀合物及其应用
RU2791445C2 (ru) Новые анти-cd19-антитела
WO2026086929A1 (zh) 靶向人b7h3的纳米抗体及其应用
WO2024067764A1 (zh) 抗gpc3单克隆抗体/双特异性抗体或其抗原结合片段及其用途
CN116997356A (zh) 抗alpp/alppl2抗体和抗体-药物缀合物